Velcade for PBL – pro
The best review of the 5 cases thus far reproted was by Sabba et al. He reproted that due to the rarity of PBL, there is no current consensual standard therapy available. As a result, PBL treatment is mirrored after aggressive NHL regimens. One of the newly emerged therapeutic options for PBL is bortezomib, which is a proteasome inhibitor and a cornerstone in MM therapy. In recently published cases, bortezomib has shown promising results in PBL. He describse a patient with HIV-negative PBL who dramatically responded to bortezomib after failing several other lines of therap and reviewed 4 other, similar cases reported in the literature. bortezomib resulted in rapid and dramatical responses regardless of the line of therapy, but they were not sustained. Thisis not sufficieint evidence to consider it SOC. Saba NS et al, .Bortezomib in plasmablastic lymphoma: a case report and review of the literature.Onkologie. 2013;36(5):287-91.
Yan MC et al, D20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014 Jul;93(1):77-80.